Désormeaux A, Bergeron M G
Centre de Recherche en Infectiologie, Centre Hospitalier Universitaire de Québec, Québec, Canada.
J Drug Target. 1998;6(1):1-15. doi: 10.3109/10611869808997877.
As the number of individuals infected with human immunodeficiency virus (HIV) is growing dramatically throughout the world, it is important to develop strategies to improve the treatment of this deadly disease. It is now well established that macrophages play a central role in HIV pathogenesis, acting as reservoirs for dissemination of virus throughout the immune system. As liposomes are naturally taken up by cells of the mononuclear phagocytic system, liposome-based therapy represents a convenient approach to improve the delivery of anti-HIV agents into infected cells improving thereby the efficacy of drugs and reducing their adverse side-effects. A more specific targeting of HIV-infected cells could also be obtained by using liposomes bearing surface attached-antibodies. This review details the applications of liposomes as drug carriers for the treatment of AIDS. It also gives an overlook of the different strategies that could be explored to control the progression of the disease in infected individuals.
随着全球感染人类免疫缺陷病毒（HIV）的人数急剧增加，制定改善这种致命疾病治疗方法的策略至关重要。现已明确，巨噬细胞在HIV发病机制中起核心作用，充当病毒在整个免疫系统中传播的储存库。由于脂质体可被单核吞噬系统的细胞自然摄取，基于脂质体的疗法是一种便捷的方法，可改善抗HIV药物向感染细胞的递送，从而提高药物疗效并减少其副作用。通过使用带有表面附着抗体的脂质体，还可以更特异性地靶向HIV感染细胞。本文综述详细介绍了脂质体作为治疗艾滋病药物载体的应用。它还概述了可探索的不同策略，以控制感染者疾病的进展。
